Prestige Consumer Healthcare Inc.
NYSE:PBHMedical - Distribution
+$0.23 today
- Market cap
- $2.40B
- Beta
- 0.35
- P/E (TTM)
- 11.6
- EPS (TTM)
- $4.01
Volume 0.62M
Average 0.67M
PBH Net Income
Bottom-line profit after all expenses, interest, and taxes.
Prestige Consumer Healthcare Inc.NYSE: PBH
Net Income · Q1 FY2027 · quarter ended Jun 2026
Net income declines year over year
Q1 FY2027 net income of $29.18M fell 38.5% year over year, behind the -19.2% change in trailing-twelve-month net income. Sequentially, it fell 45.9% from the prior quarter.
Context
- Net income amounted to 17.5% of revenue in FY2026, down 1.4 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of $220.21M (+15.7%) for the fiscal year ending Mar 2027, a step up from the -11.3% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $29.18M-45.9% QoQ
- Last fiscal yearMar 2026
- $190.3M-11.3% YoY
- LTMJun 2026
- $172.01M-19.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -38.5% | +21.0% | +59.5 pp |
| 1 year | -11.3% | +15.7% | +27.0 pp |
| 3-year CAGR | — | +11.1% | — |
| 5-year CAGR | +9.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2026
- 190.3M USD
- Year-over-year change
- -11.3%
- 4-year CAGR
- -1.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 190.3M | -11.3% |
| FY2025 | 2025-03-31 | 214.61M | +2.5% |
| FY2024 | 2024-03-31 | 209.34M | +354.3% |
| FY2023 | 2023-03-31 | (82.31M) | -140.1% |
| FY2022 | 2022-03-31 | 205.38M | — |
Net Income vs competitors
How PBH compares with its peers on the latest reported figures
- PBH's LTM Jun 2026 net income of $172.01M is the 4th highest of the 11 companies compared; the peer median is $13.95M.
- Its year-over-year change of -19.2% is the 10th highest of 11, against a peer median of +39.1%.
- Net income amounts to 15.6% of revenue for PBH, versus a peer median of 13.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $221.32M | +12.1% | +37.1% | 37.1% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $216.36M | +41.2% | -0.1% | 9.3% |
| LTM Sep 2026 | $196.08M | +190.2% | — | 13.0% | |
| LTM Jun 2026 | $172.01M | -19.2% | — | 15.6% | |
| LTM Jun 2026 | $30.09M | +181.4% | — | 1.4% | |
| LTM Jun 2026 | $28.12M | +89.5% | — | 1.2% | |
| LTM Sep 2026 | -$215K | +99.9% | — | 0.0% | |
HTFLHeartflow, Inc. Common Stock | LTM Sep 2026 | -$79.02M | +37.0% | — | 33.1% |
| LTM Mar 2026 | -$125.36M | +24.3% | — | 15.9% | |
| LTM Jun 2026 | -$188.21M | +11.4% | — | 41.9% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | -$243.1M | -34.2% | — | — |
| Peer median (excluding PBH) | $13.95M | +39.1% | +18.5% | 13.0% | |
Competitors are the stored peer set for PBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1.09B | 1.13B | 1.13B | 1.14B | 1.09B |
| Cost of Revenue | 466.17M | 502.43M | 500.91M | 503.3M | 514.07M |
| Gross Profit | 620.65M | 625.29M | 624.45M | 634.46M | 574.64M |
| Gross Margin | 57.1% | 55.4% | 55.5% | 55.8% | 52.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 264.8M | 252.42M | 259.47M | 263.93M | 265.23M |
| Operating Expenses | 290.73M | 647.71M | 282.02M | 297.69M | 265.23M |
| Depreciation & Amortization | 32.09M | 32.63M | 30.68M | 30.17M | 31.27M |
| EBITDA | 358.84M | 7.87M | 373.86M | 361.99M | 331.11M |
| EBITDA Margin | 33.0% | 0.7% | 33.2% | 31.8% | 30.4% |
| Operating Income | 329.92M | (22.42M) | 342.43M | 336.78M | 309.41M |
| Operating Margin | 30.4% | -2.0% | 30.4% | 29.6% | 28.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 64.29M | 69.16M | 67.16M | 47.63M | 42.34M |
| Other Income / Expenses | (67.46M) | (71.5M) | (66.4M) | (52.59M) | (51.91M) |
| Income Before Tax | 262.46M | (93.92M) | 276.03M | 284.19M | 257.5M |
| Pre-Tax Margin | 24.1% | -8.3% | 24.5% | 25.0% | 23.7% |
| Income Tax Expense | 57.08M | (11.61M) | 66.69M | 69.58M | 67.2M |
| Net Income | 205.38M | (82.31M) | 209.34M | 214.61M | 190.3M |
| Net Margin | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% |
| EPS (Basic) | 4.09 | (1.65) | 4.21 | 4.32 | 3.93 |
| EPS (Diluted) | 4.04 | (1.65) | 4.17 | 4.29 | 3.91 |
| Weighted Avg Shares | 50.26M | 49.88M | 49.76M | 49.7M | 48.46M |
| Weighted Avg Shares (Diluted) | 50.84M | 49.89M | 50.18M | 50.08M | 48.72M |
Prestige Consumer Healthcare Inc.
NYSE:PBH
Intrinsic Alpha fair value
Locked
Current Price
$50.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.